Craft
MEI Pharma

MEI Pharma

Revenue

$40.7 M

FY, 2022

Market Capitalization

$58.5 M

2022-09-20

MEI Pharma Summary

Company summary

Overview
MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.
Type
Public
Founded
2000
HQ
San Diego, CA, US | view all locations
Website
http://www.meipharma.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Daniel Gold

    Daniel Gold, President and Chief Executive Officer

    • Christine A. White, Non-Executive Chairman

      • Brian Drazba

        Brian Drazba, Chief Financial Officer

        • Cheryl Cohen, Non-Executive Director

          LocationsView all

          1 location detected

          • San Diego, CA HQ

            United States

            11455 El Camino Real Suite 250

          MEI Pharma Financials

          Summary financials

          Revenue (FY, 2022)
          $40.7M
          Net income (FY, 2022)
          ($54.5M)
          EBIT (FY, 2022)
          ($75.5M)

          Footer menu